title: A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies.
abstract: We report the first synthetic peptide vaccine eliciting strong CD8(+) and CD4(+) T lymphocyte responses in humans. The vaccine, representing the C-terminal region of the circumsporozoite protein of Plasmodium falciparum (amino acids 282-383) was well tolerated and strong sporozoite-specific antibodies were elicited. In addition, robust lymphocyte proliferation responses were equally elicited with concomitant in vitro production of IFN-gamma, crucial in the elimination of the parasite. Most importantly, we also observed the development of CD8(+) T lymphocyte responses decisive in the immunity to malaria. The latter finding opens new, possibly safer, avenues for vaccination strategies when a CD8(+) T cell response is needed.
authors.affiliation: Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland.
authors.forename: J A
authors.initials: JA
authors.lastname: López
authors.forename: C
authors.initials: C
authors.lastname: Weilenman
authors.forename: R
authors.initials: R
authors.lastname: Audran
authors.forename: M A
authors.initials: MA
authors.lastname: Roggero
authors.forename: A
authors.initials: A
authors.lastname: Bonelo
authors.forename: J M
authors.initials: JM
authors.lastname: Tiercy
authors.forename: F
authors.initials: F
authors.lastname: Spertini
authors.forename: G
authors.initials: G
authors.lastname: Corradin
mesh_terms: D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000918:Antibody Specificity; D000953:Antigens, Protozoan / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002478:Cells, Cultured; D005260:Female; D015234:HLA-A Antigens / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory; D007371:Interferon-gamma / Q000096:biosynthesis; D008213:Lymphocyte Activation; D017780:Malaria Vaccines / Q000009:adverse effects / Q000494:pharmacology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000628:therapy*; D008297:Male; D010446:Peptide Fragments / Q000276:immunology*; D010455:Peptides / Q000276:immunology; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D015234:HLA-A Antigens; D017780:Malaria Vaccines; D010446:Peptide Fragments; D010455:Peptides; D015800:Protozoan Proteins; D014614:Vaccines, Synthetic; C432063:circumsporozoite protein (282-383), Plasmodium falciparum; C041595:circumsporozoite protein, Protozoan; D007371:Interferon-gamma